United States Pharmaceuticals

SCYNEXIS Inc (SCYX)

Track

The most recent insider trading activity at SCYNEXIS Inc occurred on December 18, 2024. Transactions involved multiple proposed sales by 10% stockholders, specifically various Federated Hermes Kaufmann funds. These entities executed several planned divestments throughout December 2024. No insider trading activity has been reported within the last three months.
Ticker: SCYX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for SCYNEXIS Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series
10% Stockholder
2 sales — total 11,584 USD
Proposed sale 18 Dec 2024
Value US$3,344,380.25 | Price 32.14 | Shares 71,316
Proposed sale 18 Dec 2024
Value US$3,677,751.78 | Price 78.66 | Shares 67,670
Proposed sale 18 Dec 2024
Value US$4,401,493.13 | Price 376.31 | Shares 57,451
Proposed sale 18 Dec 2024
Value US$4,011,538.11 | Price 249.68 | Shares 24,050
Proposed sale 18 Dec 2024
Value US$204,590.82 | Price 1.23 | Shares 166,334
Proposed sale 18 Dec 2024
Value US$204,590.82 | Price 1.23 | Shares 166,334
Proposed sale 11 Dec 2024
Value US$13,515.24 | Price 1.23 | Shares 10,988
Proposed sale 11 Dec 2024
Value US$370,105.77 | Price 1.23 | Shares 300,899
Proposed sale 11 Dec 2024
Value US$477,378.99 | Price 1.23 | Shares 388,113
Planned buy 12 Sep 2024
Value US$27,400.00 | Price 1.37 | Shares 20,000
Proposed sale 22 Aug 2024
Value US$17,169.00 | Price 1.77 | Shares 9,700
Proposed sale 22 Aug 2024
Value US$17,169.00 | Price 1.77 | Shares 9,700
Proposed sale 22 Aug 2024
Value US$481,440.00 | Price 1.77 | Shares 272,000
Proposed sale 22 Aug 2024
Value US$481,440.00 | Price 1.77 | Shares 272,000
Proposed sale 22 Aug 2024
Value US$598,260.00 | Price 1.77 | Shares 338,000
Proposed sale 22 Aug 2024
Value US$598,260.00 | Price 1.77 | Shares 338,000
Proposed sale 9 Feb 2024
Value US$1,020,996.00 | Price 2.14 | Shares 477,101
Proposed sale 5 Feb 2024
Value US$1,262,600.00 | Price 2.14 | Shares 590,000
Proposed sale 21 Sep 2023
Value US$31,538.60 | Price 3.42 | Shares 9,214
Proposed sale 21 Sep 2023
Value US$1,232,244.00 | Price 3.42 | Shares 360,000
Buy 26 Apr 2022
Value US$225,000.00 | Price 3.00 | Shares 75,000
Buy 26 Apr 2022
Value US$10,500.00 | Price 3.00 | Shares 3,500
Sale 22 Jan 2021
Value US$302,948.55 | Price 8.95 | Shares 33,849
Sale 22 Jan 2021
Value US$2,326,832.16 | Price 8.16 | Shares 285,151
Sale 21 Jan 2021
Value US$701,100.00 | Price 7.38 | Shares 95,000
Sale 20 Jan 2021
Value US$1,374,550.00 | Price 7.43 | Shares 185,000
Buy 21 Dec 2020
Value US$31,250.00 | Price 6.25 | Shares 5,000
Buy 21 Dec 2020
Value US$20,000.00 | Price 6.25 | Shares 3,200
Buy 21 Dec 2020
Value US$3,750.00 | Price 6.25 | Shares 600
Buy 21 Dec 2020
Value US$50,000.00 | Price 6.25 | Shares 8,000
Buy 21 Dec 2020
Value US$250,000.00 | Price 6.25 | Shares 40,000
Buy 21 Dec 2020
Value US$10,000.00 | Price 6.25 | Shares 1,600
Buy 21 Dec 2020
Value US$50,000.00 | Price 6.25 | Shares 8,000
Buy 21 Dec 2020
Value US$25,000.00 | Price 6.25 | Shares 4,000
Buy 21 Dec 2020
Value US$10,000.00 | Price 6.25 | Shares 1,600
Buy 12 Dec 2019
Value US$150,000.30 | Price 0.90 | Shares 166,667
Buy 21 Aug 2019
Value US$10,545.00 | Price 1.11 | Shares 9,500
Buy 20 Aug 2019
Value US$555.00 | Price 1.11 | Shares 500
Buy 15 Aug 2019
Value US$10,115.15 | Price 1.01 | Shares 10,015
Buy 17 Apr 2019
Value US$40,750.00 | Price 1.63 | Shares 25,000
Buy 10 Jan 2019
Value US$17,250.00 | Price 0.69 | Shares 25,000
Buy 31 Dec 2018
Value US$11,500.00 | Price 0.46 | Shares 25,000
Buy 31 Dec 2018
Value US$5,950.80 | Price 0.50 | Shares 12,000
Buy 6 Sep 2018
Value US$8,890.00 | Price 1.27 | Shares 7,000
Buy 23 Aug 2018
Value US$32,250.00 | Price 1.29 | Shares 25,000
Buy 29 Mar 2018
Value US$8,160.00 | Price 1.36 | Shares 6,000
Buy 8 Mar 2018
Value US$19,999.46 | Price 1.69 | Shares 11,834
Buy 8 Mar 2018
Value US$5,000.71 | Price 1.69 | Shares 2,959
Buy 8 Mar 2018
Value US$9,999.73 | Price 1.69 | Shares 5,917
Buy 8 Mar 2018
Value US$24,995.10 | Price 1.69 | Shares 14,790
Buy 8 Mar 2018
Value US$9,730.00 | Price 1.39 | Shares 7,000
Buy 8 Mar 2018
Value US$169,000.00 | Price 1.69 | Shares 100,000
Buy 22 Sep 2017
Value US$22,300.00 | Price 2.23 | Shares 10,000
Buy 23 Aug 2017
Value US$9,237.05 | Price 1.85 | Shares 4,993
Buy 22 Aug 2017
Value US$11.27 | Price 1.61 | Shares 7
Buy 15 Aug 2017
Value US$16,100.00 | Price 1.61 | Shares 10,000
Buy 11 Aug 2017
Value US$15,500.00 | Price 1.55 | Shares 10,000
Buy 21 Jun 2017
Value US$35,000.00 | Price 1.75 | Shares 20,000
Buy 12 May 2017
Value US$25,500.00 | Price 1.70 | Shares 15,000
Buy 12 May 2017
Value US$42,250.00 | Price 1.69 | Shares 25,000
Buy 21 Dec 2016
Value US$82,500.00 | Price 3.30 | Shares 25,000
Buy 16 Dec 2016
Value US$13,000.00 | Price 3.25 | Shares 4,000
Buy 15 Sep 2016
Value US$117,600.00 | Price 2.94 | Shares 40,000
Buy 30 Jun 2016
Value US$71,694.50 | Price 2.23 | Shares 32,150
Buy 29 Jun 2016
Value US$10,464.00 | Price 2.18 | Shares 4,800
Buy 24 Jun 2016
Value US$239,000.00 | Price 2.39 | Shares 100,000
Buy 24 Jun 2016
Value US$35,850.00 | Price 2.39 | Shares 15,000
Buy 24 Jun 2016
Value US$47,800.00 | Price 2.39 | Shares 20,000
Buy 24 Jun 2016
Value US$95,600.00 | Price 2.39 | Shares 40,000
Buy 25 May 2016
Value US$18,758.04 | Price 3.26 | Shares 5,754
Buy 25 May 2016
Value US$787.20 | Price 3.20 | Shares 246
Buy 25 May 2016
Value US$15,379.00 | Price 3.64 | Shares 4,225
Buy 24 May 2016
Value US$18,535.00 | Price 3.37 | Shares 5,500
Buy 23 May 2016
Value US$9,450.00 | Price 3.15 | Shares 3,000
Buy 20 May 2016
Value US$14,130.00 | Price 3.14 | Shares 4,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stockholder

Large shareholder
71,316
32.14
US$3,344,380 		71,316 32.14 US$3,344,380
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stockholder

Large shareholder
67,670
78.66
US$3,677,752 		67,670 78.66 US$3,677,752
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
57,451
376.31
US$4,401,493 		57,451 376.31 US$4,401,493
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
128,957
1.23
US$158,617 		128,957 1.23 US$158,617
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
166,334
1.23
US$204,591 		166,334 1.23 US$204,591
2024-12-18 2024-12-18 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
166,334
1.23
US$204,591 		166,334 1.23 US$204,591
2024-12-11 2024-12-11 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stockholder

Large shareholder
10,988
1.23
US$13,515 		10,988 1.23 US$13,515
2024-12-11 2024-12-11 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity FUnds

10% Stockholder

Large shareholder
300,899
1.23
US$370,106 		300,899 1.23 US$370,106
2024-12-11 2024-12-11 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
388,113
1.23
US$477,379 		388,113 1.23 US$477,379
2024-09-16 2024-09-12 PP Planned purchase
3.9
Angulo Gonzalez David

Chief Executive Officer

Executive Director
20,000 +4.1%
1.37
US$27,400 		20,000 +4.1% 1.37 US$27,400
2024-08-27 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stockholder

Large shareholder
9,700
1.77
US$17,169 		9,700 1.77 US$17,169
2024-08-27 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
272,000
1.77
US$481,440 		272,000 1.77 US$481,440
2024-08-27 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
338,000
1.77
US$598,260 		338,000 1.77 US$598,260
2024-08-22 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stockholder

Large shareholder
9,700
1.77
US$17,169 		9,700 1.77 US$17,169
2024-08-22 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
272,000
1.77
US$481,440 		272,000 1.77 US$481,440
2024-08-22 2024-08-22 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
338,000
1.77
US$598,260 		338,000 1.77 US$598,260
2024-02-09 2024-02-09 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
477,101
2.14
US$1,020,996 		477,101 2.14 US$1,020,996
2024-02-05 2024-02-05 PrS Proposed sale
Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
590,000
2.14
US$1,262,600 		590,000 2.14 US$1,262,600
2023-09-22 2023-09-21 PrS Proposed sale
Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series

10% Stock

Large shareholder
9,214
3.42
US$31,539 		9,214 3.42 US$31,539
2023-09-22 2023-09-21 PrS Proposed sale
Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds

10% Stockholder

Large shareholder
360,000
3.42
US$1,232,244 		360,000 3.42 US$1,232,244
2022-04-28 2022-04-26 B Purchase
3.8
Taglietti Marco

Chief Executive Officer

Executive Director
75,000 +38.1%
3.00
US$225,000 		75,000 +38.1% 3.00 US$225,000
2022-04-28 2022-04-26 B Purchase
3.2
Sukenick Scott

General Counsel

Officer
3,500 +7.0%
3.00
US$10,500 		3,500 +7.0% 3.00 US$10,500
2021-01-26 2021-01-22 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
33,849 -1.8%
8.95
US$302,949 		33,849 -1.8% 8.95 US$302,949
2021-01-26 2021-01-22 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
285,151 -13.5%
8.16
US$2,326,832 		285,151 -13.5% 8.16 US$2,326,832
2021-01-26 2021-01-21 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
95,000 -4.3%
7.38
US$701,100 		95,000 -4.3% 7.38 US$701,100
2021-01-26 2021-01-20 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
185,000 -7.7%
7.43
US$1,374,550 		185,000 -7.7% 7.43 US$1,374,550
2020-12-23 2020-12-21 B Purchase
3.2
ANIDO ARMANDO
Non-Executive Director
5,000 +inf%
6.25
US$31,250 		5,000 +inf% 6.25 US$31,250
2020-12-23 2020-12-21 B Purchase
3.2
HANHAM ANN
Non-Executive Director
3,200 +758.3%
6.25
US$20,000 		3,200 +758.3% 6.25 US$20,000
2020-12-23 2020-12-21 B Purchase
3.2
Francois Eric

Chief Financial Officer

Officer
600 +5.4%
6.25
US$3,750 		600 +5.4% 6.25 US$3,750
2020-12-23 2020-12-21 B Purchase
3.2
Tinmouth Brian Philippe
Non-Executive Director
8,000 +inf%
6.25
US$50,000 		8,000 +inf% 6.25 US$50,000
2020-12-23 2020-12-21 B Purchase
3.8
Taglietti Marco

Chief Executive Officer

Executive Director
40,000 +57.4%
6.25
US$250,000 		40,000 +57.4% 6.25 US$250,000
2020-12-23 2020-12-21 B Purchase
3.2
Sukenick Scott

General Counsel

Officer
1,600 +21.3%
6.25
US$10,000 		1,600 +21.3% 6.25 US$10,000
2020-12-23 2020-12-21 B Purchase
3.2
Macdonald Guy
Non-Executive Director
8,000 +200.0%
6.25
US$50,000 		8,000 +200.0% 6.25 US$50,000
2020-12-23 2020-12-21 B Purchase
3.2
GILMAN STEVEN C
Non-Executive Director
4,000 +inf%
6.25
US$25,000 		4,000 +inf% 6.25 US$25,000
2020-12-23 2020-12-21 B Purchase
3.9
Angulo Gonzalez David

Chief Medical Officer

Officer
1,600 +7.2%
6.25
US$10,000 		1,600 +7.2% 6.25 US$10,000
2019-12-16 2019-12-12 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
166,667 +31.6%
0.90
US$150,000 		166,667 +31.6% 0.90 US$150,000
2019-08-22 2019-08-21 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
9,500 +1.8%
1.11
US$10,545 		9,500 +1.8% 1.11 US$10,545
2019-08-22 2019-08-20 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
500 +0.1%
1.11
US$555 		500 +0.1% 1.11 US$555
2019-08-19 2019-08-15 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
10,015 +2.0%
1.01
US$10,115 		10,015 +2.0% 1.01 US$10,115
2019-04-18 2019-04-17 B Purchase
3.8
Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +5.2%
1.63
US$40,750 		25,000 +5.2% 1.63 US$40,750
2019-01-14 2019-01-10 B Purchase
3.8
Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +5.5%
0.69
US$17,250 		25,000 +5.5% 0.69 US$17,250
2019-01-02 2018-12-31 B Purchase
3.8
Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +5.8%
0.46
US$11,500 		25,000 +5.8% 0.46 US$11,500
2019-01-02 2018-12-31 B Purchase
3.9
Angulo Gonzalez David

Chief Medical Officer

Officer
12,000 +10.9%
0.50
US$5,951 		12,000 +10.9% 0.50 US$5,951
2018-09-10 2018-09-06 B Purchase Angulo Gonzalez David

Chief Medical Officer

Officer
7,000 +6.9%
1.27
US$8,890 		7,000 +6.9% 1.27 US$8,890
2018-08-27 2018-08-23 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +6.2%
1.29
US$32,250 		25,000 +6.2% 1.29 US$32,250
2018-04-02 2018-03-29 B Purchase Angulo Gonzalez David

Chief Medical Officer
6,000 +6.3%
1.36
US$8,160 		6,000 +6.3% 1.36 US$8,160
2018-03-12 2018-03-08 B Purchase HASTINGS DAVID C
11,834 +59.2%
1.69
US$19,999 		11,834 +59.2% 1.69 US$19,999
2018-03-12 2018-03-08 B Purchase Sukenick Scott

General Counsel
2,959 +inf%
1.69
US$5,001 		2,959 +inf% 1.69 US$5,001
2018-03-12 2018-03-08 B Purchase Francois Eric

Chief Financial Officer
5,917 +31.1%
1.69
US$10,000 		5,917 +31.1% 1.69 US$10,000
2018-03-12 2018-03-08 B Purchase Angulo Gonzalez David

Chief Medical Officer
14,790 +20.0%
1.69
US$24,995 		14,790 +20.0% 1.69 US$24,995
2018-03-12 2018-03-08 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
100,000 +32.9%
1.69
US$169,000 		100,000 +32.9% 1.69 US$169,000
2018-03-12 2018-03-08 B Purchase Angulo Gonzalez David

Chief Medical Officer
7,000 +7.9%
1.39
US$9,730 		7,000 +7.9% 1.39 US$9,730
2017-09-25 2017-09-22 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
10,000 +3.4%
2.23
US$22,300 		10,000 +3.4% 2.23 US$22,300
2017-08-24 2017-08-23 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
4,993 +1.7%
1.85
US$9,237 		4,993 +1.7% 1.85 US$9,237
2017-08-24 2017-08-22 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
7 +0.0%
1.61
US$11 		7 +0.0% 1.61 US$11
2017-08-17 2017-08-15 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
10,000 +3.6%
1.61
US$16,100 		10,000 +3.6% 1.61 US$16,100
2017-08-14 2017-08-11 B Purchase Angulo Gonzalez David

Chief Medical Officer
10,000 +16.1%
1.55
US$15,500 		10,000 +16.1% 1.55 US$15,500
2017-06-22 2017-06-21 B Purchase HASTINGS DAVID C
20,000 +inf%
1.75
US$35,000 		20,000 +inf% 1.75 US$35,000
2017-05-15 2017-05-12 B Purchase Angulo Gonzalez David

Chief Medical Officer

Officer
15,000 +31.9%
1.70
US$25,500 		15,000 +31.9% 1.70 US$25,500
2017-05-15 2017-05-12 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +9.9%
1.69
US$42,250 		25,000 +9.9% 1.69 US$42,250
2016-12-22 2016-12-21 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
25,000 +11.1%
3.30
US$82,500 		25,000 +11.1% 3.30 US$82,500
2016-12-19 2016-12-16 B Purchase Angulo Gonzalez David

Chief Medical Officer

Officer
4,000 +9.5%
3.25
US$13,000 		4,000 +9.5% 3.25 US$13,000
2016-09-16 2016-09-15 B Purchase Machado Patrick Non-Executive Director
40,000 +200.0%
2.94
US$117,600 		40,000 +200.0% 2.94 US$117,600
2016-07-01 2016-06-30 B Purchase Angulo Gonzalez David

Chief Medical Officer

Officer
32,150 +363.3%
2.23
US$71,694 		32,150 +363.3% 2.23 US$71,694
2016-07-01 2016-06-29 B Purchase Angulo Gonzalez David

Chief Medical Officer

Officer
4,800 +118.5%
2.18
US$10,464 		4,800 +118.5% 2.18 US$10,464
2016-06-28 2016-06-24 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
100,000 +80.0%
2.39
US$239,000 		100,000 +80.0% 2.39 US$239,000
2016-06-28 2016-06-24 B Purchase Francois Eric

Chief Financial Officer

Officer
15,000 +inf%
2.39
US$35,850 		15,000 +inf% 2.39 US$35,850
2016-06-28 2016-06-24 B Purchase Machado Clarence Patrick Non-Executive Director
20,000 +inf%
2.39
US$47,800 		20,000 +inf% 2.39 US$47,800
2016-06-28 2016-06-24 B Purchase Macdonald Guy Non-Executive Director
40,000 +inf%
2.39
US$95,600 		40,000 +inf% 2.39 US$95,600
2016-05-27 2016-05-25 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
5,754 +4.8%
3.26
US$18,758 		5,754 +4.8% 3.26 US$18,758
2016-05-27 2016-05-25 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
246 +0.2%
3.20
US$787 		246 +0.2% 3.20 US$787
2016-05-27 2016-05-25 B Purchase HANHAM ANN Non-Executive Director
4,225 +inf%
3.64
US$15,379 		4,225 +inf% 3.64 US$15,379
2016-05-25 2016-05-24 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
5,500 +4.8%
3.37
US$18,535 		5,500 +4.8% 3.37 US$18,535
2016-05-24 2016-05-23 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
3,000 +2.7%
3.15
US$9,450 		3,000 +2.7% 3.15 US$9,450
2016-05-24 2016-05-20 B Purchase Taglietti Marco

Chief Executive Officer

Executive Director
4,500 +4.2%
3.14
US$14,130 		4,500 +4.2% 3.14 US$14,130
Explore more

More insider trading research around SCYNEXIS Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America